Interest  ||| S:0 E:9 ||| NN
of  ||| S:9 E:12 ||| IN
NT-proBNP  ||| S:12 E:22 ||| JJ
in  ||| S:22 E:25 ||| IN
chronic  ||| S:25 E:33 ||| JJ
heart  ||| S:33 E:39 ||| NN
failure  ||| S:39 E:47 ||| NN
follow-up  ||| S:47 E:57 ||| NN
Reducing  ||| S:57 E:66 ||| VBG
readmissions  ||| S:66 E:79 ||| NN
after  ||| S:79 E:85 ||| IN
hospitalisation  ||| S:85 E:101 ||| NN
for  ||| S:101 E:105 ||| IN
acute  ||| S:105 E:111 ||| JJ
heart  ||| S:111 E:117 ||| NN
failure  ||| S:117 E:125 ||| NN
is  ||| S:125 E:128 ||| VBZ
the  ||| S:128 E:132 ||| DT
new  ||| S:132 E:136 ||| JJ
challenge  ||| S:136 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
these  ||| S:149 E:155 ||| DT
diseases ||| S:155 E:163 ||| NNS
,  ||| S:163 E:165 ||| ,
approaching  ||| S:165 E:177 ||| VBG
30 ||| S:177 E:179 ||| CD
%  ||| S:179 E:181 ||| NN
within  ||| S:181 E:188 ||| IN
60  ||| S:188 E:191 ||| CD
to  ||| S:191 E:194 ||| TO
90  ||| S:194 E:197 ||| CD
days  ||| S:197 E:202 ||| NNS
of  ||| S:202 E:205 ||| IN
discharge ||| S:205 E:214 ||| NN
.  ||| S:214 E:216 ||| .
Congestion  ||| S:216 E:227 ||| RB
related  ||| S:227 E:235 ||| VBN
to  ||| S:235 E:238 ||| TO
high  ||| S:238 E:243 ||| JJ
ventricular  ||| S:243 E:255 ||| NNS
filling  ||| S:255 E:263 ||| VBG
pressures ||| S:263 E:272 ||| NNS
,  ||| S:272 E:274 ||| ,
reflected  ||| S:274 E:284 ||| VBD
by  ||| S:284 E:287 ||| IN
the  ||| S:287 E:291 ||| DT
high  ||| S:291 E:296 ||| JJ
levels  ||| S:296 E:303 ||| NNS
of  ||| S:303 E:306 ||| IN
natriuretic  ||| S:306 E:318 ||| JJ
peptides ||| S:318 E:326 ||| NN
,  ||| S:326 E:328 ||| ,
is  ||| S:328 E:331 ||| VBZ
the  ||| S:331 E:335 ||| DT
main  ||| S:335 E:340 ||| JJ
reason  ||| S:340 E:347 ||| NN
for  ||| S:347 E:351 ||| IN
heart  ||| S:351 E:357 ||| NN
failure  ||| S:357 E:365 ||| NN
readmission ||| S:365 E:376 ||| NN
.  ||| S:376 E:378 ||| .
Natriuretic  ||| S:378 E:390 ||| JJ
peptide  ||| S:390 E:398 ||| JJ
levels  ||| S:398 E:405 ||| NNS
are  ||| S:405 E:409 ||| VBP
a  ||| S:409 E:411 ||| DT
patent  ||| S:411 E:418 ||| NN
prognostic  ||| S:418 E:429 ||| NN
marker  ||| S:429 E:436 ||| NN
of  ||| S:436 E:439 ||| IN
cardiovascular  ||| S:439 E:454 ||| JJ
event  ||| S:454 E:460 ||| NN
in  ||| S:460 E:463 ||| IN
chronic  ||| S:463 E:471 ||| JJ
heart  ||| S:471 E:477 ||| NN
failure ||| S:477 E:484 ||| NN
.  ||| S:484 E:486 ||| .
Treshold  ||| S:486 E:495 ||| JJ
values  ||| S:495 E:502 ||| NNS
of  ||| S:502 E:505 ||| IN
BNP  ||| S:505 E:509 ||| NNP
and  ||| S:509 E:513 ||| CC
NT-proBNP  ||| S:513 E:523 ||| JJ
being  ||| S:523 E:529 ||| VBG
respectively  ||| S:529 E:542 ||| RB
125  ||| S:542 E:546 ||| CD
and  ||| S:546 E:550 ||| CC
1000  ||| S:550 E:555 ||| CD
pg ||| S:555 E:557 ||| CD
/ ||| S:557 E:558 ||| CD
mL ||| S:558 E:560 ||| NN
.  ||| S:560 E:562 ||| .
Optimizing  ||| S:562 E:573 ||| JJ
treatment  ||| S:573 E:583 ||| NN
of  ||| S:583 E:586 ||| IN
heart  ||| S:586 E:592 ||| NN
failure  ||| S:592 E:600 ||| NN
by  ||| S:600 E:603 ||| IN
monitoring  ||| S:603 E:614 ||| VBG
natriuretic  ||| S:614 E:626 ||| JJ
peptides ||| S:626 E:634 ||| NN
,  ||| S:634 E:636 ||| ,
including  ||| S:636 E:646 ||| VBG
management  ||| S:646 E:657 ||| NN
of  ||| S:657 E:660 ||| IN
diuretic  ||| S:660 E:669 ||| JJ
doses ||| S:669 E:674 ||| NNS
,  ||| S:674 E:676 ||| ,
remains  ||| S:676 E:684 ||| VBZ
matter  ||| S:684 E:691 ||| NN
of  ||| S:691 E:694 ||| IN
controversies ||| S:694 E:707 ||| NNS
.  ||| S:707 E:709 ||| .
